Results 161 to 170 of about 2,680 (197)

Eravacycline, a newly approved fluorocycline [PDF]

European Journal of Clinical Microbiology and Infectious Diseases, 2019
Complicated intra-abdominal infections (cIAIs) are commonly associated with multimicroorganisms and treatment choices are becoming narrower due to developing resistance, especially in the gram-negative Enterobacteriaceae species. Eravacycline is a newly developed, fully synthetic tetracycline derivative that has shown potent broad-spectrum activity ...
Young R Lee
exaly   +12 more sources

Some of the next articles are maybe not open access.

Related searches:

Evaluation of Eravacycline: A Novel Fluorocycline

Pharmacotherapy, 2020
Eravacycline (ERV), formerly known as TP‐434, is a novel tetracycline (TET) antibiotic that exhibits in vitro activity against various gram‐positive, gram‐negative aerobic and anaerobic pathogens, including those exhibiting TET‐specific acquired resistance mechanisms.
Sara Alosaimy, Jacinda C Abdul-Mutakabbir, Michael Joseph Rybak   +2 more
exaly   +3 more sources

Eravacycline: The Tetracyclines Strike Back

Annals of Pharmacotherapy, 2019
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of eravacycline, a novel fluorocycline antibiotic from the tetracycline family. Data Sources: A PubMed search was conducted for data between 1946 and March 2019 using MeSH terms eravacycline and TP-434.
Monica V Mahoney, Jason C Gallagher
exaly   +3 more sources

Prolonged course of eravacycline leading to acute pancreatitis

The American Journal of the Medical Sciences, 2023
Eravacycline is the newest member of the broad-spectrum class of tetracycline antimicrobials. Pancreatitis has been previously associated with the tetracycline class of antibiotics, but, to our knowledge, we believe that this is the first reported case of eravacycline-induced pancreatitis.
Sylvia S, Stefanos, Lyndsey, Davis, Amruta, Panwala, Michael S, Gelfand, Chinelo N, Animalu, B Tate, Cutshall   +5 more
openaire   +2 more sources

A Divergent Route to Eravacycline

The Journal of Organic Chemistry, 2017
A convergent route to eravacycline (1) has been developed by employing Michael-Dieckmann cyclization between enone 3 and a fully built and protected left-hand piece (LHP, 2). After construction of the core eravacycline structure, a deprotection reaction was developed, allowing for the isoxazole ring opening and global deprotection to be achieved in one
Wu-Yan Zhang, Qinglin Che, Scott Crawford, Magnus Ronn, Nicholas Dunwoody   +4 more
openaire   +2 more sources